In the era of Bortezomib-based induction, intensification of Melphalan-based conditioning with Bortezomib does not improve survival outcomes in newly diagnosed multiple myeloma: a study from the chronic malignancies working party of the EBMT
Bortezomib (Vel)- Melphalan 200 mg/m2 (Mel200) (Vel-Mel) has been utilised to intensify conditioning in autologous hematopoietic stem cell transplantation (AHCT) for multiple myeloma (MM). This EBMT registry-based study compared Vel-Mel with Mel200 during upfront AHCT. Between 2010 and 2017, MM pati...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
31 January 2024
|
| In: |
Bone marrow transplantation
Year: 2024, Jahrgang: 59, Heft: 4, Pages: 526-533 |
| ISSN: | 1476-5365 |
| DOI: | 10.1038/s41409-023-02160-8 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41409-023-02160-8 Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41409-023-02160-8 
|
| Verfasserangaben: | Meral Beksac, Diderik-Jan Eikema, Linda Koster, Cyrille Hulin, Xavier Poiré, Rose-Marie Hamladji, Tomasz Gromek, Ali Bazarbachi, Zubeyde Nur Ozkurt, Thomas Pabst, Tarek Ben Othman, Jürgen Finke, Olga Pirogova, Depei Wu, Amjad Hayat, Inken Hilgendorf, Eleni Tholouli, Liesbeth C. de Wreede, Stefan Schönland, Laurent Garderet, Joanna Drozd-Sokolowska, Kavita Raj, Patrick J. Hayden, Ibrahim Yakoub-Agha and Donal P. McLornan |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 189277643X | ||
| 003 | DE-627 | ||
| 005 | 20250117233419.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240701s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41409-023-02160-8 |2 doi | |
| 035 | |a (DE-627)189277643X | ||
| 035 | |a (DE-599)KXP189277643X | ||
| 035 | |a (OCoLC)1475301019 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Beksaç, Meral |e VerfasserIn |0 (DE-588)1334511810 |0 (DE-627)1892777436 |4 aut | |
| 245 | 1 | 0 | |a In the era of Bortezomib-based induction, intensification of Melphalan-based conditioning with Bortezomib does not improve survival outcomes in newly diagnosed multiple myeloma |b a study from the chronic malignancies working party of the EBMT |c Meral Beksac, Diderik-Jan Eikema, Linda Koster, Cyrille Hulin, Xavier Poiré, Rose-Marie Hamladji, Tomasz Gromek, Ali Bazarbachi, Zubeyde Nur Ozkurt, Thomas Pabst, Tarek Ben Othman, Jürgen Finke, Olga Pirogova, Depei Wu, Amjad Hayat, Inken Hilgendorf, Eleni Tholouli, Liesbeth C. de Wreede, Stefan Schönland, Laurent Garderet, Joanna Drozd-Sokolowska, Kavita Raj, Patrick J. Hayden, Ibrahim Yakoub-Agha and Donal P. McLornan |
| 264 | 1 | |c 31 January 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 01.07.2024 | ||
| 520 | |a Bortezomib (Vel)- Melphalan 200 mg/m2 (Mel200) (Vel-Mel) has been utilised to intensify conditioning in autologous hematopoietic stem cell transplantation (AHCT) for multiple myeloma (MM). This EBMT registry-based study compared Vel-Mel with Mel200 during upfront AHCT. Between 2010 and 2017, MM patients who received Vel-Mel (n = 292) conditioning were compared with 4,096 Mel200 patients in the same 58 centres. Pre-AHCT, compared to Mel200 patients, Vel-Mel patients had similar International Staging System (ISS) scores and cytogenetic risk profiles; a similar proportion had received bortezomib-based induction (85% and 87.3%, respectively) though they were younger with a better performance status. Vel-Mel patients were more likely to achieve CR post-induction (40.6% vs 20.3%, p < 0.001) and by day 100 of AHCT (CR/VGPR: 70.2 % vs. 57.2%, p < 0.001). There was no difference in 3-year PFS (49% vs 46%, p = 0.06) or early post-AHCT mortality. In multivariable analysis, Vel-Mel associated with inferior PFS (HR: 1.69 (1.27-2.25, p < 0.001) and OS (HR:1.46 (1.14-1.86,p = 0.002), similar to negative effects on PFS of advanced ISS (HR:1.56 (1.33-1.83, p < 0.001), high-risk cytogenetics (HR:1.43(1.18-1.74, p < 0.001) and poor post-induction response(<=PR)(HR: 1.43(1.25-1.62, p < 0.001) Overall, despite superior pre- and post-AHCT responses, there was no improvement in PFS or OS following Vel-Mel. This data supports the findings of the smaller prospective IFM study. | ||
| 650 | 4 | |a Myeloma | |
| 650 | 4 | |a Stem-cell therapies | |
| 700 | 1 | |a Eikema, Diderik-Jan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Koster, Linda |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hulin, Cyrille |e VerfasserIn |4 aut | |
| 700 | 1 | |a Poiré, Xavier |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hamladji, Rose-Marie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gromek, Tomasz |e VerfasserIn |4 aut | |
| 700 | 1 | |8 1\p |a Bazarbachi, Ali |e VerfasserIn |0 (DE-588)1189768747 |0 (DE-627)1668480697 |4 aut | |
| 700 | 1 | |a Ozkurt, Zubeyde Nur |e VerfasserIn |4 aut | |
| 700 | 1 | |8 2\p |a Pabst, Thomas |d 1963- |e VerfasserIn |0 (DE-588)123238900 |0 (DE-627)082432317 |0 (DE-576)293617155 |4 aut | |
| 700 | 1 | |a Ben Othman, Tarek |e VerfasserIn |4 aut | |
| 700 | 1 | |8 3\p |a Finke, Jürgen |e VerfasserIn |0 (DE-588)1096178028 |0 (DE-627)856561029 |0 (DE-576)467887586 |4 aut | |
| 700 | 1 | |a Pirogova, Olga |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wu, Depei |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hayat, Amjad |e VerfasserIn |4 aut | |
| 700 | 1 | |8 4\p |a Hilgendorf, Inken |d 1974- |e VerfasserIn |0 (DE-588)123769884 |0 (DE-627)082756864 |0 (DE-576)293870411 |4 aut | |
| 700 | 1 | |a Tholouli, Eleni |e VerfasserIn |4 aut | |
| 700 | 1 | |8 5\p |a Wreede, Liesbeth Cornelia de |e VerfasserIn |0 (DE-588)1088593844 |0 (DE-627)849722942 |0 (DE-576)289337631 |4 aut | |
| 700 | 1 | |a Schönland, Stefan |d 1969- |e VerfasserIn |0 (DE-588)122405226 |0 (DE-627)705896137 |0 (DE-576)293255792 |4 aut | |
| 700 | 1 | |8 6\p |a Garderet, Laurent |d 1964- |e VerfasserIn |0 (DE-588)1161564748 |0 (DE-627)1024850803 |0 (DE-576)506738337 |4 aut | |
| 700 | 1 | |a Drozd-Sokolowska, Joanna |e VerfasserIn |4 aut | |
| 700 | 1 | |8 7\p |a Raj, Kavita |e VerfasserIn |0 (DE-588)1308920849 |0 (DE-627)1869506685 |4 aut | |
| 700 | 1 | |a Hayden, Patrick J. |e VerfasserIn |4 aut | |
| 700 | 1 | |8 8\p |a Yakoub-Agha, Ibrahim |e VerfasserIn |0 (DE-588)1017074054 |0 (DE-627)690277938 |0 (DE-576)353090204 |4 aut | |
| 700 | 1 | |8 9\p |a McLornan, Donal |e VerfasserIn |0 (DE-588)1337879401 |0 (DE-627)1897714637 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bone marrow transplantation |d London : Springer Nature, 1997 |g 59(2024), 4, Seite 526-533 |h Online-Ressource |w (DE-627)320433366 |w (DE-600)2004030-1 |w (DE-576)091012996 |x 1476-5365 |7 nnas |a In the era of Bortezomib-based induction, intensification of Melphalan-based conditioning with Bortezomib does not improve survival outcomes in newly diagnosed multiple myeloma a study from the chronic malignancies working party of the EBMT |
| 773 | 1 | 8 | |g volume:59 |g year:2024 |g number:4 |g pages:526-533 |g extent:8 |a In the era of Bortezomib-based induction, intensification of Melphalan-based conditioning with Bortezomib does not improve survival outcomes in newly diagnosed multiple myeloma a study from the chronic malignancies working party of the EBMT |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41409-023-02160-8 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/s41409-023-02160-8 |x Verlag |z kostenfrei |3 Volltext |
| 883 | |8 1\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 2\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 3\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 4\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 5\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 6\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 7\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 8\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 9\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 951 | |a AR | ||
| 992 | |a 20240701 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 122405226 |a Schönland, Stefan |m 122405226:Schönland, Stefan |d 910000 |d 910100 |d 50000 |e 910000PS122405226 |e 910100PS122405226 |e 50000PS122405226 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 19 | ||
| 999 | |a KXP-PPN189277643X |e 4544562473 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 01.07.2024"],"id":{"doi":["10.1038/s41409-023-02160-8"],"eki":["189277643X"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"recId":"189277643X","relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedKey":"1997","publisher":"Springer Nature ; Macmillan ; Nature Publishing Group","dateIssuedDisp":"1997-","publisherPlace":"London ; Basingstoke ; London"}],"disp":"In the era of Bortezomib-based induction, intensification of Melphalan-based conditioning with Bortezomib does not improve survival outcomes in newly diagnosed multiple myeloma a study from the chronic malignancies working party of the EBMTBone marrow transplantation","type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 17.01.25"],"id":{"eki":["320433366"],"issn":["1476-5365"],"zdb":["2004030-1"]},"part":{"volume":"59","pages":"526-533","text":"59(2024), 4, Seite 526-533","extent":"8","year":"2024","issue":"4"},"pubHistory":["Nachgewiesen 19.1997 -"],"title":[{"title_sort":"Bone marrow transplantation","title":"Bone marrow transplantation"}],"recId":"320433366","language":["eng"]}],"title":[{"title":"In the era of Bortezomib-based induction, intensification of Melphalan-based conditioning with Bortezomib does not improve survival outcomes in newly diagnosed multiple myeloma","subtitle":"a study from the chronic malignancies working party of the EBMT","title_sort":"In the era of Bortezomib-based induction, intensification of Melphalan-based conditioning with Bortezomib does not improve survival outcomes in newly diagnosed multiple myeloma"}],"name":{"displayForm":["Meral Beksac, Diderik-Jan Eikema, Linda Koster, Cyrille Hulin, Xavier Poiré, Rose-Marie Hamladji, Tomasz Gromek, Ali Bazarbachi, Zubeyde Nur Ozkurt, Thomas Pabst, Tarek Ben Othman, Jürgen Finke, Olga Pirogova, Depei Wu, Amjad Hayat, Inken Hilgendorf, Eleni Tholouli, Liesbeth C. de Wreede, Stefan Schönland, Laurent Garderet, Joanna Drozd-Sokolowska, Kavita Raj, Patrick J. Hayden, Ibrahim Yakoub-Agha and Donal P. McLornan"]},"physDesc":[{"noteIll":"Illustrationen","extent":"8 S."}],"person":[{"family":"Beksaç","display":"Beksaç, Meral","given":"Meral","role":"aut"},{"display":"Eikema, Diderik-Jan","family":"Eikema","given":"Diderik-Jan","role":"aut"},{"family":"Koster","display":"Koster, Linda","given":"Linda","role":"aut"},{"role":"aut","family":"Hulin","display":"Hulin, Cyrille","given":"Cyrille"},{"role":"aut","display":"Poiré, Xavier","family":"Poiré","given":"Xavier"},{"role":"aut","given":"Rose-Marie","display":"Hamladji, Rose-Marie","family":"Hamladji"},{"family":"Gromek","display":"Gromek, Tomasz","given":"Tomasz","role":"aut"},{"role":"aut","display":"Bazarbachi, Ali","family":"Bazarbachi","given":"Ali"},{"family":"Ozkurt","display":"Ozkurt, Zubeyde Nur","given":"Zubeyde Nur","role":"aut"},{"given":"Thomas","family":"Pabst","display":"Pabst, Thomas","role":"aut"},{"display":"Ben Othman, Tarek","family":"Ben Othman","given":"Tarek","role":"aut"},{"role":"aut","family":"Finke","display":"Finke, Jürgen","given":"Jürgen"},{"display":"Pirogova, Olga","family":"Pirogova","given":"Olga","role":"aut"},{"role":"aut","given":"Depei","family":"Wu","display":"Wu, Depei"},{"role":"aut","given":"Amjad","display":"Hayat, Amjad","family":"Hayat"},{"role":"aut","given":"Inken","display":"Hilgendorf, Inken","family":"Hilgendorf"},{"role":"aut","family":"Tholouli","display":"Tholouli, Eleni","given":"Eleni"},{"given":"Liesbeth Cornelia de","display":"Wreede, Liesbeth Cornelia de","family":"Wreede","role":"aut"},{"family":"Schönland","display":"Schönland, Stefan","given":"Stefan","role":"aut"},{"given":"Laurent","display":"Garderet, Laurent","family":"Garderet","role":"aut"},{"given":"Joanna","family":"Drozd-Sokolowska","display":"Drozd-Sokolowska, Joanna","role":"aut"},{"role":"aut","family":"Raj","display":"Raj, Kavita","given":"Kavita"},{"family":"Hayden","display":"Hayden, Patrick J.","given":"Patrick J.","role":"aut"},{"role":"aut","given":"Ibrahim","display":"Yakoub-Agha, Ibrahim","family":"Yakoub-Agha"},{"role":"aut","family":"McLornan","display":"McLornan, Donal","given":"Donal"}],"origin":[{"dateIssuedDisp":"31 January 2024","dateIssuedKey":"2024"}]} | ||
| SRT | |a BEKSACMERAINTHEERAOF3120 | ||